abbrev. CLL updates and conference notes

[Guest guest]

Clinical Applications Conference in NY

Incorporated most of my notes here:

http://www.lymphomation.org/type-CLL.htm

in section on Treatments

Other:

= CLL cell birth to death rates correlates with disease progression.

Range: .11 to 1.76% birth rates per day.

= Heterogeneity (differences in cytogenetic abnormalities):

stage of maturation of malignant clones

antigen reactivity - auto or foreign antigen

antigen binding properties (specificity and response)

Unmutated - 90% autoreactive

80% polyreactive

= CD38+ & ZAP 70 has dynamic influence on heterogeneity of clones

such as on:

cd69, HLA-R, -2

cell cycling; Ki-67 cell; shorter telomerese

= Seems like the correct approach: studies in CLL look at molecular subtypes and

correlate response to specific molecular defects.

= Not quite definitive, but obtaining minimal residual disease from treatment is

associated with improved survival.

= There's a need to do comparative studies to define which of the many promising

combination therapies is best and for which cytogenetic group.

- Karl